Stock BIOC GLAXOSMITHKLINE S.A.E
Add to a list
To use this feature you must be a member
Log inSign up

Financials GlaxoSmithKline S.A.E

Equities

BIOC

EGS38171C012

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 06:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
31.08 EGP +3.32% Intraday chart for GlaxoSmithKline S.A.E -3.84% -12.57%
Mar. 04 GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,650 1,650 1,416 2,579 3,187 2,969
Enterprise Value (EV) 1 1,344 1,634 1,540 2,685 2,671 2,237
P/E ratio - 11.6 x 50.4 x 16.7 x 4.33 x 49.1 x
Yield - - - 2.43% - 2.11%
Capitalization / Revenue 1.02 x 0.97 x 0.71 x 1.42 x 1.75 x 1.33 x
EV / Revenue 0.83 x 0.96 x 0.77 x 1.48 x 1.46 x 1 x
EV / EBITDA 9.85 x 5.68 x 6.67 x 9.65 x 55 x 4.7 x
EV / FCF 8.25 x -5.54 x 16.1 x 54.1 x 24.6 x 12.8 x
FCF Yield 12.1% -18% 6.22% 1.85% 4.06% 7.79%
Price to Book - 1.36 x 1.17 x 1.9 x 1.84 x 1.51 x
Nbr of stocks (in thousands) 83,514 83,514 83,514 83,514 83,514 83,514
Reference price 2 - 19.76 16.96 30.88 38.16 35.55
Announcement Date 9/26/19 5/1/20 5/30/22 5/30/22 3/18/24 3/18/24
1EGP in Million2EGP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,623 1,704 1,993 1,812 1,823 2,240
EBITDA 1 136.4 287.9 230.9 278.3 48.6 475.6
EBIT 1 110.1 267.6 202.5 242.2 15.33 441.5
Operating Margin 6.79% 15.7% 10.16% 13.36% 0.84% 19.71%
Earnings before Tax (EBT) 1 66.48 197.2 91.9 179.4 -62.94 119.7
Net income 1 49.92 142.6 28.13 154.6 735.4 60.46
Net margin 3.07% 8.37% 1.41% 8.53% 40.33% 2.7%
EPS 2 0.4075 1.708 0.3368 1.852 8.805 0.7239
Free Cash Flow 1 162.8 -294.8 95.72 49.65 108.4 174.2
FCF margin 10.03% -17.3% 4.8% 2.74% 5.94% 7.78%
FCF Conversion (EBITDA) 119.34% - 41.45% 17.84% 222.99% 36.63%
FCF Conversion (Net income) 326.18% - 340.25% 32.11% 14.74% 288.14%
Dividend per Share 2 0.5000 - - 0.7500 - 0.7500
Announcement Date 9/26/19 5/1/20 5/30/22 5/30/22 3/18/24 3/18/24
1EGP in Million2EGP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 124 106 - -
Net Cash position 1 307 16 - - 516 732
Leverage (Debt/EBITDA) - - 0.5352 x 0.3823 x - -
Free Cash Flow 1 163 -295 95.7 49.7 108 174
ROE (net income / shareholders' equity) 4.69% 12.4% 2.32% 12% -7.38% 3.27%
ROA (Net income/ Total Assets) 3.5% 7.58% 5.62% 6.66% 0.34% 8.18%
Assets 1 1,426 1,881 500.5 2,320 215,401 738.7
Book Value Per Share 2 12.90 14.60 14.50 16.30 20.70 23.50
Cash Flow per Share 2 3.670 3.010 0.2700 0.8800 7.010 9.930
Capex 1 84.6 133 53.7 35.8 48.8 77.1
Capex / Sales 5.21% 7.81% 2.69% 1.97% 2.67% 3.44%
Announcement Date 9/26/19 5/1/20 5/30/22 5/30/22 3/18/24 3/18/24
1EGP in Million2EGP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
GLAXOSMITHKLINE S.A.E Stock GlaxoSmithKline S.A.E
-12.57% 54.13M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BIOC Stock
  4. Financials GlaxoSmithKline S.A.E